2 Equal-Weighted ETFs For Potentially Better Performance
Investing.com | May 21, 2021 14:33
Equal-weighted exchange-traded funds (ETFs) invest equal amounts in businesses irrespective of their market capitalizations. Conversely, a cap-weighted index, allows companies with larger market caps to have a significant impact on the index value. In recent decades, capitalization-weighted indexing has become the dominant methodology.
For example, the S&P 500 is a market-cap-weighted index, and the SPDR® S&P 500 (NYSE:SPY) gives access to this index. Apple (NASDAQ:AAPL), whose market cap is $2.08 trillion, has the highest weighting (5.65%) in SPY, followed by Microsoft (NASDAQ:MSFT) and Amazon (NASDAQ:AMZN). The top 10 stocks comprise about 28% of the fund.
Recent research led by Bernd Hanke of concludes that equal-weighted funds offer greater diversification and typically perform better.
Against that background, here are two equally-weighted ETFs that could appeal to investors who do not want to buy top-heavy funds concentrated in a handful of stocks.
h2 1. Invesco S&P 500 Equal Weight ETF/h2
Current Price: $149.15
52-Week Range: $94.86 - $152.85
Dividend Yield: 1.36%
Expense Ratio: 0.20% per year
The Invesco S&P 500® Equal Weight ETF (NYSE:RSP) is an equal-weighted version of SPY. Since its inception in April 2003, net assets have reached $27.8 billion.
RSP tracks the S&P 500 Equal Weighted Index, which equally weights the stocks in the S&P 500 Index. Both the index and the fund are rebalanced quarterly.
The top 10 stocks comprise close to 2.5% of the fund. Among the leading names are the steelmaker Nucor (NYSE:NUE), railroad and line-haul operator Kansas City Southern (NYSE:KSU), consumer credit reporting agency Equifax (NYSE:EFX), electronic data storage group Seagate Technology (NASDAQ:STX) and package delivery giant United Parcel Service (NYSE:UPS). The giant tech companies, including Apple, MSFT and AMZN, each have a weighting of 0.20%.
In the past 12 months, RSP is up almost 56% and has returned 16.1% year-to-date (YTD). By comparison, SPY is up 40.8% in the past year and 9.9% YTD. Put another way, the size factor has meant that RSP has outperformed SPY in recent months. Both ETFs hit all-time highs in early May.
Get The App
We believe the fund could be appropriate for most long-term portfolios. Its forward P/E and P/B ratios stand at 20.76 and 3, respectively. A potential decline toward $145 or below would offer better value.
h2 2. SPDR S&P Biotech ETF/h2Current Price: $127.57
52-Week Range: $97.15 - $174.79
Dividend Yield: 0.26%
Expense Ratio: 0.35% per year
This fund comes from the health space. The SPDR® S&P Biotech ETF (NYSE:XBI) invests in 170 biotechnology stocks. The fund started trading in January 2006, and net assets stand at $6.8 billion.
XBI tracks the S&P Biotechnology Select Industry, which is equal-weighted. Around 9.5% of the fund is in the top 10 companies, whose market caps range from $1.1 billion to $63.5 billion.
Among the top names in its roster: Curis (NASDAQ:CRIS), which concentrates on cancer treatments; United Therapeutics (NASDAQ:UTHR), which focuses is on treatment of chronic and life-threatening conditions; biopharma group Alexion Pharmaceuticals (NASDAQ:ALXN); Moderna (NASDAQ:MRNA), which has developed one of the leading vaccines against COVID-19; and Humanigen (NASDAQ:HGEN), which focuses on rare diseases.
Most analysts concur that the biotechnology sector is innovative. The rush to develop vaccines and treatments for the pandemic is a testament to the growth potential of the industry. In the past 12 months, XBI returned more than 21% and hit an all-time high on Feb. 9. However, YTD, the fund is down 11.2%. We like the diversity of the fund. Potential investors could consider investing in XBI around these levels.
On a final note, by comparison, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB), which is a cap-weighted fund, has returned 11% in the past 12 months, but is down almost 2% YTD. It is another widely-followed ETF with close to $10 billion under management.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.